The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growthin vitro
作者:
Jürgen Sonnemann,
Vera Eckervogt,
Borna Truckenbrod,
Joachim Boos,
Winfried Winkelmann,
Frans van Valen,
期刊:
Anti-Cancer Drugs
(OVID Available online 2003)
卷期:
Volume 14,
issue 9
页码: 767-771
ISSN:0959-4973
年代: 2003
出版商: OVID
关键词: bisphosphonates;bone tumor;clodronate;Ewing's sarcoma;pamidronate;statins
数据来源: OVID
摘要:
The MTT assay was used to measure the effects of pamidronate, clodronate and mevastatin on the cell viability of Ewing's sarcoma cell lines 6647, CADO-ES-1, ES-2, ES-3, RD-ES, SK-ES-1, STA-ET-2.1 and VH-64. Treatment of these cells with pamidronate inhibited cell viability in a time- and dose-dependent manner. After a 72-h incubation period with 50 μM pamidronate, cell numbers were reduced by up to 80%, whereas the monophosphonate analog 3-aminopropyl phosphonate had no effect at concentrations up to 2 mM. Clodronate reduced cell viability by maximally 40% at 1 mM. These data provide the first evidence for a direct growth-inhibitory effect of pamidronate on Ewing's sarcoma cells. Hence, pamidronate definitely merits a more thorough exploration into its potential use in the therapy of patients with Ewing's sarcoma.
点击下载:
PDF
(115KB)
返 回